What Is an ePRO and Why Should You Use It for High-Quality Real-World Data Collection?

Written by
Florentin Ory
Published on
01 Oct 25
Updated on
16 Nov 26
ePRO on your patients' own phones
Key takeaways
  • An ePRO collects patient answers on a smartphone, tablet or computer and timestamps each entry (EMA, 2023).
  • In a BMJ study, actual compliance was 11% with paper diaries and 94% with electronic diaries (Stone et al., 2002).
  • For a limited migration of a validated questionnaire, the FDA considers new comparability evidence unlikely to be needed (2025).
  • A participant without a smartphone should not be excluded: the sponsor must offer another way to answer (EMA, 2023).

In a clinical trial, real-world data collection is essential. Among the different methods available, the use of an ePRO (electronic Patient Reported Outcome) proves particularly advantageous. At the core of this approach lies a fundamental philosophy: putting the patient at the center of the clinical study by simplifying their experience and giving them the means to actively contribute to medical research. But what exactly is an ePRO, and why should you use it to ensure high-quality real-world data collection?

What Is an ePRO?

An ePRO is a tool that enables direct data collection from patients via smartphones, tablets, or computers, by having them answer questionnaires through a digital interface. This method stands out from traditional paper-based data collection approaches.

The Advantages of Using an ePRO for High-Quality Real-World Data Collection

Improved Data Quality

By allowing patients to self-report their symptoms and health status, the use of an ePRO reduces bias and data entry errors. Patients are often better equipped to accurately describe their symptoms and experiences, leading to more reliable and relevant data. In addition, ePROs enable real-time data capture, which minimizes the risks of forgetfulness or confusion.

Real-time reporting is crucial because it captures the patient’s condition at the exact moment symptoms occur, reducing recall bias and providing a more accurate picture of their health evolution. This immediacy also allows research teams to quickly detect warning signs.

An Optimized Patient Experience

ePRO solutions transform the patient’s experience in clinical trials by simplifying and humanizing the data collection process. Unlike traditional, often burdensome paper methods, ePRO adapts to the patient’s lifestyle and technological preferences. This user-centered approach encourages a more natural and less stressful participation, turning the patient from a passive subject into an active partner in research.

Multichannel Flexibility and BYOD (Bring Your Own Device)

Modern ePRO solutions provide maximum flexibility through multichannel access, allowing patients to choose the input method that best suits them: smartphone, tablet, or laptop. The BYOD concept enables participants to use their own familiar devices, eliminating technological barriers and boosting adoption.

This flexibility is crucial to accommodate diverse patient populations, whether tech-savvy or less comfortable with digital tools, ensuring maximum inclusivity in clinical trials.

Facilitating Real-World Patient Follow-Up

With an ePRO, patients can be monitored remotely, without needing to travel to a clinical study site. It also enables long-term data collection, making it easier to evaluate the efficacy and safety of treatments over time.

Enhanced Patient Compliance

By enabling patients to self-report their health status, ePROs increase their engagement and commitment to the clinical trial. Patients gain a better understanding of the study’s purpose and are more likely to follow treatment instructions. Additionally, the interactive and user-friendly format of ePROs can motivate patients to participate more actively in the study.

At CHRU Strasbourg, patients completed 85% of the questionnaires themselves on a real-world sleep study.

Simplified Monitoring and Quality Control

Since ePROs collect data directly through a digital interface, the monitoring and quality control processes are greatly simplified. Data can be easily reviewed and validated, ensuring high quality and reliability of results. Moreover, ePRO use standardizes data collection, which streamlines statistical analysis.

Integration With Other Systems via APIs

An ePRO equipped with an API (Application Programming Interface) allows seamless integration of collected data with other systems such as electronic health records (EHR), clinical trial management systems (CTMS), or data analytics platforms. This not only saves time but also improves the quality and consistency of clinical data.

Using an ePRO in clinical trials brings numerous advantages in terms of data quality, patient follow-up, compliance, and operational efficiency, making it an essential solution for modern, patient-centric research.

How does ePRO compare with a paper diary?

An ePRO records the actual time of each answer; a paper diary only carries the date and time the patient writes in it. In a study published in the BMJ in 2002, Stone and colleagues followed 80 adults with chronic pain for 21 days: 40 kept a paper diary and 40 an electronic diary. On paper, patients recorded 90% of their entries as made within the scheduled window, while light sensors fitted in the diary binder, which logged each opening, found only 11%. The electronic diary, which sent audible prompts and blocked any entry outside the window, reached 94% actual compliance.

The table compares the paper diary and ePRO on five points that affect data quality.

Point of comparisonPaper diaryePRO
Time of entryUnknown: the diary only shows what the patient writes in itTimestamped by the system at the moment of entry, not only at submission (EMA, 2023)
Actual compliance (Stone et al., BMJ, 2002)11% of entries within the scheduled window, versus 90% reported94% of entries within the scheduled window
Batch completionNo diary opening on 32% of days, yet the diary showed 92% of the entries scheduled on those days (Stone et al., BMJ, 2002)Visible: the timestamp shows when the patient entered each answer
RemindersNo automatic reminderSchedule with alerts or reminders, which the EMA recommends considering to support compliance (2023)
Source documentDiary returned to the investigator, who keeps the original or a certified copy (FDA, 2009)Answer saved on the device, then a certified copy on the server after a validated transfer (EMA, 2023)

In its 2009 PRO guidance, the FDA says it reviews the protocol to see what steps the sponsor takes so that patients complete their diary according to the trial schedule, and not just before the clinic visit when the site collects it. With an ePRO, you can check this answer by answer from the timestamps.

For implementation, our guide How to collect patient-reported outcomes with ePRO covers seven steps, from choosing the instruments to tracking compliance. Our article eCOA vs ePRO places ePRO among eCOA assessments and compares BYOD with provisioned devices.

[[faq]]

Sources

ePRO on your patients' own phones
See Datacapt on your own study
We cover your follow-up schedule and patient population, then show BYOD collection and the link to the EDC.
A 30-minute call on your protocol, your sites and the modules you need.

Frequently asked questions

Still have a question? Talk to our team.

What is the difference between a PRO and an ePRO?

The PRO (patient-reported outcome) is the measurement itself. The FDA defines it as a measurement based on a report that comes directly from the patient about the status of their health condition, without amendment or interpretation by a clinician or anyone else. An ePRO collects the same measurements on a smartphone, tablet or computer instead of paper.

Is a questionnaire validated on paper still valid as an ePRO?

Yes, if the migration is limited. In its October 2025 guidance on clinical outcome assessments (COA), the FDA considers additional evidence of comparability unlikely to be necessary when the changes are small to moderate and the sponsor follows migration best practices, such as those of the Critical Path Institute's ePRO Consortium.

Do you need to provide a device to patients without a smartphone?

You need to offer them another way to answer, for example a device provided by the sponsor. Under the EMA guideline on computerised systems (2023), a participant who is unable or unwilling to use their own device (BYOD) should not be excluded from the trial. The sponsor should also define the minimum technical specifications for participants' devices.

Can a patient correct an ePRO answer after submitting it?

The application usually does not allow it. The EMA expects a correction procedure, based on a trial-specific risk assessment and initiated promptly by the patient or site staff. If site staff initiate it, they rely on a written record, such as the patient's email or a phone note. The original answer must remain visible or accessible in the audit trail.

Does 21 CFR Part 11 apply to ePRO data?

Yes, for a trial under an IND or IDE, or one supporting an FDA submission. The FDA's 2009 PRO guidance refers to Part 11 and asks for an audit trail of every change to the data once they leave the patient's device. In the EU, the EMA applies the same ICH E6 standards to ePRO as to other collection methods.

Florentin Ory
CEO & Co-Founder

Florentin combines clinical research know-how with a true passion for product design. Attentive to detail and obsessed with user experience, he ensures that Datacapt remains a high-performance platform that’s also intuitive and accessible to every user.